Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 618 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: blood transfusion Clear all
Not listed Not applicable Interventional

Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management

NCT01686659
View directory record Official record
Conditions
Surgery
Interventions
Continuous Noninvasive Hemoglobin Monitoring
Device
Lead sponsor
Society for the Advancement of Blood Management, Inc
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Stanford, California • The Bronx, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Phase 4 Interventional Results available

Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?

NCT01714336
View directory record Official record
Conditions
Hip Fracture
Interventions
tranexamic acid, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Not applicable Interventional

Use of Cell Salvage Post-operatively in Infants to Decrease Use of Allogeneic Blood Product Transfusions

NCT01211366
View directory record Official record
Conditions
Transfusion
Interventions
Cell Saver RBCs, Conventional volume infusion
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population

NCT03923959
View directory record Official record
Conditions
Hip Fractures
Interventions
Tranexamic Acid Injectable Solution, Placebo
Drug · Other
Lead sponsor
Lancaster General Hospital
Other
Eligibility
65 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 15, 2026, 4:03 AM EDT
Withdrawn Early Phase 1 Interventional

Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation

NCT04383756
View directory record Official record
Conditions
Transfusion Related Complication, Liver Transplant
Interventions
Donor Blood, Banked Blood
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 15, 2026, 4:03 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets

NCT03787927
View directory record Official record
Conditions
Bleeding, Platelet Dysfunction Due to Drugs, Platelet Dysfunction
Interventions
Autologous Platelet Transfusion (room-temperature-stored), Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (cold-stored 15 days), Aspirin, Clopidogrel
Drug
Lead sponsor
Bloodworks
Other
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

NCT04294641
View directory record Official record
Conditions
Chronic GVHD
Interventions
Ibrutinib, ECG, PFT's, CT, Steroid pulse (prednisone), Voriconazole, Posaconazole, Azithromycin, Montelukast, Budesonide, Beclomethasone, Filgrastim, Pegfilgrastim, Erythropoietin, Transfusions, Oral/Skin biopsy
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Bethesda, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease

NCT00071032
View directory record Official record
Conditions
Anemia, Hematologic Diseases, Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Thromboembolism, Pneumonia, Cerebrovascular Accident
Interventions
Liberal (10 g/dL) Transfusion Strategy, Restrictive (Symptomatic) Transfusion Strategy
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
50 Years and older
Enrollment
2,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02807558
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Tamibarotene, Azacitidine, Daratumumab
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
14
States / cities
Hartford, Connecticut • Miami, Florida • Iowa City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 15, 2026, 4:03 AM EDT
Not listed Not applicable Interventional

The TAPS Trial - Fetoscopic Laser Surgery for Twin Anemia Polycythemia Sequence

NCT04432168
View directory record Official record
Conditions
Twin Anemia Polycythemia Sequence
Interventions
Fetoscopic Laser Surgery, Standard Treatment
Procedure · Other
Lead sponsor
Leiden University Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Not applicable Interventional

Combining Restrictive Guidelines and a NIRS SCORE to Decrease RBC Transfusions

NCT02535208
View directory record Official record
Conditions
Anemia of Prematurity (AOP)
Interventions
Restrictive transfusions based on SCOR assessment, Liberal transfusions
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 3 Days
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Phase 4 Interventional Results available

Effects of Microplegia on Transfusion Rates After Cardiac Surgery

NCT05076604
View directory record Official record
Conditions
Aortic Valve Disease, Mitral Valve Disease
Interventions
Cardioplegia Solution, Microplegic Solution No. 1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Phase 4 Interventional Results available

Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty

NCT02664909
View directory record Official record
Conditions
Femoral Neck Fractures
Interventions
Tranexamic Acid, Placebo (saline)
Drug
Lead sponsor
UConn Health
Other
Eligibility
55 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Farmington, Connecticut • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 15, 2026, 4:03 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Sickle Cell Anemia With Stem Cell Transplant

NCT01350232
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia
Interventions
Fludarabine, Cytarabine, Cellular Infusions, Total Body Irradiation, Cyclophosphamide, Bortezomib, Rituximab, Plasmapheresis
Drug · Device · Radiation + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 15, 2026, 4:03 AM EDT
Terminated Not applicable Interventional

Thromboelastography Transfusion Protocol for Pediatric Neuromuscular Scoliosis Surgery

NCT02670798
View directory record Official record
Conditions
Neuromuscular Scoliosis
Interventions
Thromboelastography laboratory testing
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage

NCT02229513
View directory record Official record
Conditions
Postpartum Hemorrhage, Uterine Atony
Interventions
Uterine Cooling
Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Results available

Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets

NCT02078284
View directory record Official record
Conditions
Thrombocytopenia
Interventions
CPP, LSP
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Lebanon, New Hampshire • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of Leukoreduced Blood Transfusions on Infection Following Trauma

NCT00135291
View directory record Official record
Conditions
Wounds and Injuries
Interventions
Leukoreduced blood transfusion
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2008 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Not applicable Interventional Results available

Preventing Acute Chest Syndrome by Transfusion Feasibility Study

NCT00951808
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Single blood transfusion, Standard care
Biological · Behavioral
Lead sponsor
Carelon Research
Other
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 15, 2026, 4:03 AM EDT
Active, not recruiting Not applicable Interventional

Trial of Indication-Based Transfusion of Red Blood Cells in ECMO

NCT05405426
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation, Red Blood Cell Transfusion, Organ Failure, Multiple
Interventions
Red blood cell transfusion
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Days to 6 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Results available

Biotin-RBC Transfusion in SCD

NCT04426591
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
Drug · Device
Lead sponsor
Marianne Yee
Other
Eligibility
2 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

NCT04374149
View directory record Official record
Conditions
Cytokine Release Syndrome, COVID19
Interventions
Therapeutic Plasma Exchange, Ruxolitinib
Procedure · Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
12 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 15, 2026, 4:03 AM EDT
Not listed Phase 1 Interventional

Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

NCT01165762
View directory record Official record
Conditions
ESRD
Interventions
Immune Tolerance
Drug
Lead sponsor
Everett Meyer
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Stanford, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 15, 2026, 4:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Decision Aid for Therapeutic Options In Sickle Cell Disease

NCT02326597
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Hemoglobin SS, Hemoglobin SC, Hemoglobin Beta Thalassemia
Interventions
Decision Aid Tool, Standard Practice
Other
Lead sponsor
Emory University
Other
Eligibility
8 Years to 80 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 15, 2026, 4:03 AM EDT